Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
Halozyme Therapeutics (NASDAQ: HALO) announced that its President and CEO, Dr. Helen Torley, will present at the upcoming BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET. The company will provide a live audio webcast of the presentation on their Investor Relations website, with replays available for 90 days after the conference.
Halozyme Therapeutics (NASDAQ: HALO) ha annunciato che la sua Presidente e CEO, la Dott.ssa Helen Torley, parteciperà alla prossima Conferenza Sanitaria BofA Securities 2025. La presentazione è prevista per martedì 13 maggio alle 16:20 PT / 19:20 ET. La società trasmetterà in diretta audio la presentazione sul sito web delle Relazioni con gli Investitori, con la possibilità di rivederla per 90 giorni dopo la conferenza.
Halozyme Therapeutics (NASDAQ: HALO) anunció que su Presidenta y CEO, la Dra. Helen Torley, presentará en la próxima Conferencia de Salud BofA Securities 2025. La presentación está programada para el martes 13 de mayo a las 4:20 pm PT / 7:20 pm ET. La compañía ofrecerá una transmisión en vivo de audio de la presentación en su sitio web de Relaciones con Inversionistas, con repeticiones disponibles durante 90 días después de la conferencia.
Halozyme Therapeutics (NASDAQ: HALO)는 대표이자 CEO인 헬렌 토를리 박사가 다가오는 BofA 증권 2025 헬스케어 컨퍼런스에서 발표할 예정임을 발표했습니다. 발표는 5월 13일 화요일 오후 4:20 PT / 오후 7:20 ET에 예정되어 있습니다. 회사는 투자자 관계 웹사이트에서 발표의 라이브 오디오 웹캐스트를 제공하며, 컨퍼런스 후 90일 동안 다시보기 서비스를 제공합니다.
Halozyme Therapeutics (NASDAQ: HALO) a annoncé que sa Présidente et CEO, le Dr Helen Torley, présentera lors de la prochaine Conférence Santé BofA Securities 2025. La présentation est prévue pour le mardi 13 mai à 16h20 PT / 19h20 ET. La société proposera une retransmission audio en direct de la présentation sur son site web des Relations Investisseurs, avec des rediffusions disponibles pendant 90 jours après la conférence.
Halozyme Therapeutics (NASDAQ: HALO) gab bekannt, dass seine Präsidentin und CEO, Dr. Helen Torley, auf der bevorstehenden BofA Securities 2025 Healthcare Conference präsentieren wird. Die Präsentation ist für Dienstag, den 13. Mai um 16:20 Uhr PT / 19:20 Uhr ET geplant. Das Unternehmen wird eine Live-Audio-Webcast der Präsentation auf seiner Investor-Relations-Website anbieten, wobei Wiederholungen für 90 Tage nach der Konferenz verfügbar sind.
- None.
- None.
The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET.
A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference-302446419.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When is Halozyme (HALO) presenting at the BofA Securities Healthcare Conference 2025?
Who will represent Halozyme (HALO) at the BofA Securities Healthcare Conference?
How can investors access Halozyme's presentation at the BofA Securities Conference?
What type of meetings will Halozyme (HALO) conduct at the BofA Securities Conference?
